The validity and utility of the MD Anderson symptom inventory in patients with prostate cancer: Evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the eastern cooperative oncology group

Clinical Genitourinary Cancer

Volumn 12, Issue 1, 2014, Pages 41-49

  Jones, Desiree ^a   Zhao, Fengmin ^b   Fisch, Michael J ^a   Wagner, Lynne I ^c   Patrick Miller, Linda J ^d   Cleeland, Charles S ^a   Mendoza, Tito R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

ECOG; MDASI; Patient reported outcome; Symptom assessment; Validation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONSTIPATION; COUGHING; CRONBACH ALPHA COEFFICIENT; DIARRHEA; DISTRESS SYNDROME; DROWSINESS; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MD ANDERSON SYMPTOM INVENTORY; MIDDLE AGED; NAUSEA; PAIN; PARESTHESIA; PROSTATE CANCER; QUALITY OF LIFE; RASH; SLEEP DISORDER; SYMPTOM; TEST RETEST RELIABILITY; VALIDATION STUDY; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; YOUNG ADULT;

ECOG; MDASI; PATIENT-REPORTED OUTCOME; SYMPTOM ASSESSMENT; VALIDATION;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84892440598     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.07.003     Document Type: Article

References (24)

1. G. Colloca, and P. Colloca Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need? Med Oncol 28 2011 519 527
2. K. Rnic, W. Linden, and I. Tudor et al. Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments Prostate Cancer Prostatic Dis 16 2013 111 122
3. J.E. Esther Kim, M.J. Dodd, and B.E. Aouizerat et al. A review of the prevalence and impact of multiple symptoms in oncology patients J Pain Symptom Manage 37 2009 715 736
4. E. Basch, A.P. Abernethy, and C.D. Mullins et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology J Clin Oncol 30 2012 4249 4255
5. C.M. Reilly, D.W. Bruner, and S.A. Mitchell et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment Support Care Cancer 21 2013 1525 1550
6. P. Esper, F. Mo, and G. Chodak et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument Urology 50 1997 920 928
7. G. van Andel, A. Bottomley, and S.D. Fossa et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer Eur J Cancer 44 2008 2418 2424
8. M.S. Litwin, R.D. Hays, and A. Fink et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure Med Care 36 1998 1002 1012
9. K.M. Szymanski, J.T. Wei, and R.L. Dunn et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors Urology 76 2010 1245 1250
10. M.R. Stockler, D. Osoba, and P. Goodwin et al. Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer J Clin Epidemiol 51 1998 137 145
11. Symptom Management and Quality of Life Steering Committee. Clinical trials meeting on building bridges: the identification of core symptoms and health-related quality of life domains for use in cancer resarch. Available at: http://transformingtrials.cancer.gov/files/SxQOLSCPROCTPMExecutive%20Summary- FINAL.pdf. Accessed: February 19, 2013.
12. C.S. Cleeland, T.R. Mendoza, and X.S. Wang et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory Cancer 89 2000 1634 1646
13. R.C. Serlin, T.R. Mendoza, and Y. Nakamura et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function Pain 61 1995 277 284
14. Cleeland CS. The M.D. Anderson Symptom Inventory user guide [draft]. Available at: http://www.mdanderson.org/mdasi. Accessed: February 19, 2013.
15. StataCorp Stata Statistical Software: release 11 2009 StataCorp LP College Station, TX
16. rd ed. 1994 McGraw-Hill New York
17. G.R. Norman, J.A. Sloan, and K.W. Wyrwich Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation Med Care 41 2003 582 592
18. J.A. Sloan, D. Cella, and R.D. Hays Clinical significance of patient-reported questionnaire data: another step toward consensus J Clin Epidemiol 58 2005 1217 1219
19. C.E. Metz Basic principles of ROC analysis Semin Nucl Med 8 1978 283 298
20. T.S. Armstrong, T. Mendoza, and I. Gning et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) J Neurooncol 80 2006 27 35
21. T.R. Mendoza, X.S. Wang, and C. Lu et al. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory Oncologist 16 2011 217 227
22. D. Jones, E.G. Vichaya, and X.S. Wang et al. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module J Hematol Oncol 6 2013 13
23. D.L. Berry Patient-reported symptoms and quality of life integrated into clinical cancer care Semin Oncol Nurs 27 2011 203 210
24. R.A. Mesa, J. Gotlib, and V. Gupta et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial J Clin Oncol 31 2013 1285 1292